stockrow
Friday 6 November 2026
Export MANE’s income statement to Excel — free account
Veradermics Incorporated
MANE Healthcare Biotechnology
138.19
9.59
+7.46%
Follow MANE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
70.53 | 59.12 | 16.66 | — |
+2 more quarters Free account |
Net Debt/EBITDA |
27.74 | 13.09 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.62 | 0.71 | 0.00 | 0.87 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(0.36) | (0.93) | 0.00 | (21.00) | |
Cash per Share |
20.28 | 17.21 | 0.00 | 0.00 | |
Shareholders Equity per Share |
20.12 | 17.21 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
20.12 | 17.21 | 0.00 | 0.00 | |
Free Cash Flow |
(14.51) | (21.17) | (71.63) | (15.64) | |
Working Capital |
813.05 | 390.35 | 143.34 | — | |
Capital Expenditures |
(0.02) | — | (0.02) | 0.00 | |
Net Current Asset Value |
812.62 | 390.35 | (121.14) | 0.00 | |
| Other line items | |||||
Quick Ratio |
70.11 | 58.19 | 15.50 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.36) | (0.93) | 0.00 | (21.00) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Assets |
412.87 | 226.45 | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026